Doubts emerge over Anthropic IPO valuation and growth trajectory
Critics argue that Anthropic's high valuation ignores a slowing revenue trend and unrealistic promises in the medical sector.
The short version
- Anthropic's revenue growth has reportedly slowed down following a peak in Q2.
- Critics argue that the company's revenue trajectory is no longer accelerating as fast as needed for a gargantuan business.
- The analysis suggests that increased competition from Chinese models has led users to watch their spending more carefully.
- Some observers describe Anthropic's promises regarding medical applications as 'absolutely absurd' and unrealistic.
Why it matters
For investors, this highlights the risk of overvaluing AI companies based on past exponential growth rather than current trends. For the public, it raises questions about the feasibility of high-stakes AI promises in critical fields like medicine.
The bull case for Anthropic
Anthropic has established itself as a major player in the artificial intelligence space by developing some of the strongest models currently available. Many observers believe the company holds a slight edge over its competitors in terms of model quality and performance.
Because of this technical lead, many investors have built a strong bull case for the company's upcoming initial public offering (IPO). This perspective assumes that the company will continue to see its revenue climb steadily as it scales its operations and expands its market reach.
The core of this argument relies on the idea that Anthropic can maintain its momentum and become a sustainable, massive business. Supporters point to the high demand for its technology as a primary indicator that the company is on a path toward significant financial success.
The trillion-pound baby fallacy
Critics of the current valuation point to a phenomenon they call the 'trillion-pound baby fallacy.' This concept suggests that while growth can appear exponential for a period, very few companies can maintain that level of acceleration forever.
Recent data suggests that Anthropic's revenue rocket may have already fallen off its previous pace. While the second quarter saw a significant spike, the most recent figures indicate that the growth is no longer accelerating at the rate required to support a gargantuan business structure.
The analysis suggests that the Q2 peak was a special moment in time. It occurred during a period of high demand before Chinese models caught up to the competition, which may have temporarily inflated the growth narrative.
Changing market dynamics
The landscape for AI usage is shifting as more options become available to consumers and businesses. As more models enter the market, users are becoming more discerning about how they allocate their resources and spend their money.
This shift means that people are watching their token spend—the amount of data processed by the AI—more carefully than they did in the past. When users are more conscious of costs, it naturally leads to a leveling out of revenue for the dominant providers.
As garymarcus.substack.com reported, this transition from a period of unchecked spending to one of careful management poses a challenge for Anthropic's long-term financial projections. The company must now find ways to maintain its position in a more price-sensitive and competitive environment.
Unrealistic medical promises
Beyond the financial metrics, there are significant concerns regarding the types of promises Anthropic is making to the public. Specifically, the company's claims regarding its capabilities in the medical field have drawn sharp criticism from some observers.
Some critics argue that these promises are entirely unrealistic and lack a basis in current technological reality. They suggest that the company may be overpromising on what AI can actually achieve in high-stakes environments like healthcare, where the margin for error is non-existent.
The analysis suggests that these 'wilder promises' are a major point of contention for those looking at the company's long-term viability. It raises questions about whether the company is prioritizing marketing hype over the practical limitations of its current technology.
What comes next for investors
As Anthropic prepares for its IPO, the discrepancy between its high valuation and its slowing growth rate will be a primary focus for the market. Investors will need to decide if the company's technical strengths are enough to offset the cooling of the initial AI hype cycle.
The company faces the difficult task of proving it can build a sustainable business model that doesn't rely on perpetual exponential growth. It must navigate a world where users have more choices and are increasingly looking for value rather than just novelty.
Ultimately, the success of the IPO may depend on whether Anthropic can deliver on its core technology while tempering its more ambitious claims. Observers will be watching closely to see if the revenue stabilizes or if the company can find a new way to drive growth in a maturing market.
What to watch
- Whether Anthropic's revenue continues to level out in the coming quarters.
- How competition from Chinese models impacts the pricing of AI tokens.
- The actual progress made on Anthropic's medical AI applications.
Try it
Look up the recent revenue trends for major AI companies to see if they are following a similar leveling-off pattern.
Sources and links
First reported by garymarcus.substack.com. Written by the SI Agent News Desk from the reporting above.Written with AI from the source above. Every number is checked against the source. Spot a mistake? Corrections.
Liked it? Say why
Add a line for other readers.
No account needed. We never show your email. Comments with links, ads or abuse are held and not shown. Your comment shows after a quick check.